Global Viral Clearance Market

Viral Clearance Market Size, Share, Growth Analysis, By Type(Viral Removal Method, Viral Inactivation Method, Viral Detection Method), By Application(Recombinant Proteins, Blood, Blood Products, Vaccines), By End User(Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Others), By Method(Viral Removal Method, Viral Inactivation Method, Viral Detection Method), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2288 | Region: Global | Published Date: February, 2024
Pages: 260 | Tables: 120 | Figures: 77

Viral Clearance Market Competitive Landscape

The key players in the viral clearance market are working on continuous innovation in the field of research and development and product portfolio enhancement for better therapeutic outcomes for consumers. For example, In November 2021, Wuxi biologics announced the official opening of its advanced therapies testing facility, including 140,000 sq. ft laboratories to enhance the company’s Contract Testing, Developing, and manufacturing Organization businesses to meet the increasing needs of customers in cell and gene therapy industry. Companies are also focusing on mergers and acquisitions to expand their businesses.

Viral Clearance Market Top Players Company Profiles

  • Charles River Laboratories International, Inc.
  • Merck KGaA
  • Wuxi AppTec Inc.
  • Eurofins Scientific
  • Avance Biosciences Inc.
  • Lonza Group AG
  • Sigma-Aldrich Corporation
  • Sartorius AG
  • Texcell, Inc.
  • Kedrion Biopharma Inc.
  • ViruSure GmbH
  • Clean Cells Inc.
  • Cytovance Biologics Inc.
  • GE Healthcare Life Sciences
  • Vironova AB
  • F. Hoffmann-La Roche Ltd.
  • BSL Bioservice Scientific Laboratories GmbH
  • Nelson Laboratories LLC
  • BioReliance Corporation
  • Novartis AG

Viral Clearance Market Recent Development

  • In June 2022, Asahi Kasei Medical is expanding into the CDMO business with the acquisition of Bay Area biologics maker Bionova Scientific for an undisclosed price. Like many in the industry, Japan-based Asahi Kasei has been on an expansion tear during the past few years. It purchased Austrian viral safety testing services provider Virusure Forschung und Entwicklung in 2019 and last year snapped up U.S-based mycoplasma testing services company Bionique Testing Labs.
  • In August 2021, WuXi Biologics announced that just 13 months after receiving its first GMP certificate, it has also received European Medicines Agency (EMA) GMP certificate for Biosafety testing center in Suzhou. This certificate demonstrates WuXi Biologics’ compliance with international cGMP safety assessment standards and regulatory guidelines.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Viral Clearance Market size was valued at USD 492.9 billion in 2019 and is poised to grow from USD 535.6 billion in 2023 to USD 1519.7 billion by 2031, growing at a CAGR of 16.1% in the forecast period (2024-2031).

The key players in the viral clearance market are working on continuous innovation in the field of research and development and product portfolio enhancement for better therapeutic outcomes for consumers. For example, In November 2021, Wuxi biologics announced the official opening of its advanced therapies testing facility, including 140,000 sq. ft laboratories to enhance the company’s Contract Testing, Developing, and manufacturing Organization businesses to meet the increasing needs of customers in cell and gene therapy industry. Companies are also focusing on mergers and acquisitions to expand their businesses. 'Charles River Laboratories International, Inc.', 'Merck KGaA', 'Wuxi AppTec Inc.', 'Eurofins Scientific', 'Avance Biosciences Inc.', 'Lonza Group AG', 'Sigma-Aldrich Corporation', 'Sartorius AG', 'Texcell, Inc.', 'Kedrion Biopharma Inc.', 'ViruSure GmbH', 'Clean Cells Inc.', 'Cytovance Biologics Inc.', 'GE Healthcare Life Sciences', 'Vironova AB', 'F. Hoffmann-La Roche Ltd.', 'BSL Bioservice Scientific Laboratories GmbH', 'Nelson Laboratories LLC', 'BioReliance Corporation', 'Novartis AG'

Growing Demand for Generics and Biosimilars: Increasing demand for biosimilars and generics is an ongoing trend. The need for sophisticated and cheap therapies for chronic diseases around the world is driving demand for recombinant non-glycosylation proteins in the biosimilars market; the application of cutting-edge technology to increase avenues.

In 2022, North America dominated the market by accounting for over 35% of the market share owing to the rapidly growing innovation in biotechnology and Life sciences. Growth of pharmaceuticals, increase in number of drug approvals, investments in research and development, and accuracy and flexibility of method in life sciences research has shaped the market growth in these areas. The growing prevalence of illnesses and an increased production of monoclonal antibodies, and government assistance for medication development are some of the primary reasons driving the viral clearance industry in the US with increasing pharmaceutical production supporting the growth of the region. Europe is expected to follow North America due to the strong foundation of research and development and pharmaceuticals and is expected to capture the second-largest share of the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Viral Clearance Market

Report ID: SQMIG35I2288

$5,300
BUY NOW GET FREE SAMPLE